Prior Authorization

AETNA BETTER HEALTH ILLINOIS FAMILY HEALTH PLAN (MEDICAID)

Forteo (Medicaid)

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Aetna Better Health Illinois at **1-844-242-0908**.

When conditions are met, we will authorize the coverage of Forteo (Medicaid).

Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug Name (please circle)				
FORTEO (teriparatide)				
Please specify:				
Quantity	Frequency	_ Strer	ngth	
Route of Administration	_ Expected Length of therapy _			
Patient Information				
Patient Name:				
· · · · · · · · · · · · · · · · · · ·				
Patient Phone:				
Prescribing Physician				
Physician Name:				
Specialty:	NPI Number:			
Physician Fax:	Physician Pho	ne:		
Physician Address:	City, State, Zip	D:		
Diagnosis:	ICD Code:			
Please circle the appropriate answer	for each question.			
Has the patient received a Forteo therapy?	total of 24 months of	Υ	N	
[If yes, no further questions	s.]			
Is Forteo requested for the in a man or a postmenopa	•	Υ	N	
[If no, skip to question 8.]				
3. Does the patient have a lo 2.5 SD (standard deviation 2.5 or less) OR does the p fracture at the hip, spine, v Reference Number: C6576-A/ Effective	ns) below normal (T-score - atient have a fragility vrist, arm, rib, or pelvis?	Υ	N	

	If yes, submit records or document T-score and date:		
	[If no, then no further questions.]		
4.	Is the request for a male patient?	Υ	N
	[If no, skip to question 13.]		
5.	Does the patient have normal testosterone levels?	Υ	N
	Submit labs or document result and date:		
	[If yes, skip to question 13.]		
6.	Is the patient receiving testosterone replacement therapy?	Υ	N
	[If yes, skip to question 13.]		
7.	Does the patient have a history of prostate cancer?	Υ	N
	[If yes, skip to question 13.]		
	[If no, then no further questions.]		
8.	Is Forteo being used for the treatment of corticosteroid-induced osteoporosis?	Υ	N
	[If no, then no further questions.]		
9.	Is the request for a PREmenopausal woman or a man less than 50 years old?	Υ	N
	[If no, then skip to question 11.]		
10.	Does the patient have a history of a fragility fracture?	Υ	N
	[If yes, skip to question 12.]		
	[If no, then no further questions.]		
11.	Is the request for a postmenopausal woman or a man 50 years of age or older?	Υ	N
	[If no, then no further questions.		
12.	Has the patient received, or is expected to receive, at least 7.5mg/day of prednisone (or equivalent) for at least 3 months?	Υ	N

Reference Number: C6576-A/ Effective Date: 02/22/2017

Pres	scriber (Or Authorized) Signature	Dat	e			
affirm that the information given on this form is true and accurate as of this date.						
Con	nments:					
	[No further questions.]					
14	Does the patient meet ONE of the following? A) Decreased T-score after at least 2 years of compliant therapy with at least one formulary oral bisphosphonate (i.e., alendronate), B) New fracture while taking an oral bisphosphonate (i.e., alendronate), or C) Contraindication or SEVERE intolerance to oral bisphosphonates (i.e., current upper GI symptoms, inability to swallow, osteonecrosis of the jaw, or inability to remain in an upright position after oral bisphosphonate administration for the required length of time) If yes, submit records or provide details here:	,	N			
	If yes, submit labs or document result and date: ———————————————————————————————————					
	(Note: Patients who are vitamin D deficient should have vitamin D replaced before starting treatment with Forteo.)					
13	Does the patient have a 25-hydroxyvitamin D level above 20ng/mL?	,	N			
	lif no, then no further questions.]					

Reference Number: C6576-A/ Effective Date: 02/22/2017